S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
NASDAQ:OPNT

Opiant Pharmaceuticals News Headlines

$27.07
-2.12 (-7.26%)
(As of 01/14/2022 04:00 PM ET)
Add
Compare
Today's Range
$25.40
$29.14
50-Day Range
$24.03
$36.79
52-Week Range
$8.51
$37.71
Volume
131,269 shs
Average Volume
56,954 shs
Market Capitalization
$127.77 million
P/E Ratio
541.51
Dividend Yield
N/A
Beta
0.51
Get Opiant Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Opiant Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OPNT
News Sentiment

-0.07

0.31

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OPNT Articles
This Week

12

1

OPNT Articles
Average Week



Opiant Pharmaceuticals (NASDAQ:OPNT) News Headlines Today

SourceHeadline
MarketBeat logo Brokerages Anticipate Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Will Announce Quarterly Sales of $13.68 Million
americanbankingnews.com - January 16 at 5:22 AM
MarketBeat logoZacks: Analysts Anticipate Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) to Announce $0.10 EPS
americanbankingnews.com - January 14 at 4:14 AM
nasdaq.com logoOpiant Pharmaceuticals, Inc. Common Stock (OPNT)
nasdaq.com - January 13 at 9:22 PM
insidertrades.com logoInsider Selling: Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Insider Sells 385 Shares of Stock
insidertrades.com - January 12 at 6:46 PM
MarketBeat logoDavid D. O'toole Sells 432 Shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Stock
americanbankingnews.com - January 12 at 6:46 PM
MarketBeat logoOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) CEO Roger Crystal Sells 1,058 Shares
americanbankingnews.com - January 12 at 6:46 PM
MarketBeat logoOpiant Pharmaceuticals (NASDAQ:OPNT) Stock Price Crosses Above Two Hundred Day Moving Average of $22.94
americanbankingnews.com - January 11 at 2:20 AM
finance.yahoo.com logoDoes Opiant Pharmaceuticals (NASDAQ:OPNT) Have A Healthy Balance Sheet?
finance.yahoo.com - January 4 at 9:32 AM
finance.yahoo.com logoOpiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - December 20 at 6:26 PM
finance.yahoo.com logoOPNT: Raises 2021 Full-Year Revenue and Cash Guidance...
finance.yahoo.com - November 15 at 3:24 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - November 11 at 7:48 PM
finance.yahoo.com logoOpiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 10 at 6:53 PM
nasdaq.com logoHealth Check: How Prudently Does Opiant Pharmaceuticals (NASDAQ:OPNT) Use Debt?
nasdaq.com - November 8 at 3:02 PM
finance.yahoo.com logoInvesting in Opiant Pharmaceuticals (NASDAQ:OPNT) five years ago would have delivered you a 279% gain
finance.yahoo.com - November 5 at 2:25 PM
finance.yahoo.com logoOpiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - November 4 at 6:40 PM
finance.yahoo.com logoOpiant Announces Publication of Manuscript Treatment of Overdose in the Synthetic Opioid Era in Peer-Reviewed Journal Pharmacology & Therapeutics
finance.yahoo.com - November 2 at 5:50 PM
au.finance.yahoo.com logoGlobal Corrugated Equipment Market to Reach a Value of USD 310.32 Million by 2028 : Fior Markets
au.finance.yahoo.com - October 23 at 9:53 AM
finance.yahoo.com logoOpiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
finance.yahoo.com - October 21 at 7:28 PM
nasdaq.com logoOpiant Pharmaceuticals Inc Shares Climb 1.7% Past Previous 52-Week High - Market Mover
nasdaq.com - September 16 at 5:00 PM
finance.yahoo.com logoOpiant Pharmaceuticals to Participate in September Investor Conferences
finance.yahoo.com - August 25 at 5:56 PM
finance.yahoo.com logoBullish: Analysts Just Made A Huge Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
finance.yahoo.com - August 7 at 9:24 AM
finance.yahoo.com logoOPNT: PD Data for OPNT003 Expected 4Q21…
finance.yahoo.com - August 6 at 12:30 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - August 5 at 8:28 PM
finance.yahoo.com logoOpiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
finance.yahoo.com - July 22 at 6:11 PM
finance.yahoo.com logoOpiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - July 20 at 5:57 PM
finance.yahoo.com logoOPNT: Positive Results for OPNT003 PK Study; PD Results in 4Q21...
finance.yahoo.com - July 13 at 9:27 PM
finance.yahoo.com logoOpiant Jumps on Opioid Overdose Treatment Results
finance.yahoo.com - July 7 at 5:52 PM
baystreet.ca logoOpiant Jumps on Results
baystreet.ca - July 7 at 12:51 PM
markets.businessinsider.com logoMid-Day Market Update: Crude Oil Down 2.5%; Opiant Pharmaceuticals Shares Jump
markets.businessinsider.com - July 7 at 12:51 PM
finance.yahoo.com logoOpiant Pharma Stock Surges On Positive Nasal Nalmefene Data In Opioid Overdose Study
finance.yahoo.com - July 7 at 12:51 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose
finance.yahoo.com - July 6 at 8:08 PM
benzinga.com logoLooking Into Opiant Pharmaceuticals's Return On Capital Employed
benzinga.com - June 18 at 12:33 PM
benzinga.com logoOpiant Pharmaceuticals: Return On Capital Employed Insights
benzinga.com - June 3 at 7:10 PM
finance.yahoo.com logoOpiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 24 at 7:41 PM
finance.yahoo.com logoOpiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT
finance.yahoo.com - May 18 at 7:16 PM
nasdaq.com logoOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
nasdaq.com - May 14 at 7:06 PM
finance.yahoo.com logoOPNT: PK and PD Trials for OPNT003 Underway…
finance.yahoo.com - May 13 at 12:56 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update
finance.yahoo.com - May 11 at 5:53 PM
finance.yahoo.com logoOpiant Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
finance.yahoo.com - May 3 at 6:37 PM
nasdaq.com logoIs Opiant Pharmaceuticals (NASDAQ:OPNT) Using Debt Sensibly?
nasdaq.com - April 29 at 7:37 PM
finance.yahoo.com logoOpiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone
finance.yahoo.com - April 5 at 6:35 PM
markets.businessinsider.com logoThe Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract
markets.businessinsider.com - April 1 at 9:09 AM
finance.yahoo.com logoOpiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
finance.yahoo.com - March 31 at 6:08 PM
feeds.benzinga.com logoOpiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.
feeds.benzinga.com - March 22 at 4:28 PM
finance.yahoo.com logoOPNT: NDA Filing on Track for 4Q21…
finance.yahoo.com - March 9 at 1:13 PM
finance.yahoo.com logoOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Just Released Its Full-Year Earnings: Here's What Analysts Think
finance.yahoo.com - March 6 at 9:23 AM
markets.businessinsider.com logoThe Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
markets.businessinsider.com - March 5 at 9:15 AM
finance.yahoo.com logoOpiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 4 at 8:21 PM
finance.yahoo.com logoRecap: Opiant Pharmaceuticals Q4 Earnings
finance.yahoo.com - March 4 at 8:21 PM
markets.businessinsider.com logoOpiant Pharmaceuticals Inc hosts conference call for investors
markets.businessinsider.com - February 26 at 12:54 PM
Get Opiant Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feed

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.